Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893119 | 1.00 | PIK3CD (0.42) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL16480429 | 0.81 | MAPT (0.49) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL16480374 | 0.81 | MAPT (0.49) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL19711138 | 0.79 | PIK3CD (0.61) | PIK3CDMAPTGAATSHRATM | |
| SCHEMBL9892937 | 0.79 | HSD11B1 (0.39) | MAPTHSD11B1NR1H2NR1H3GAA | |
| SCHEMBL9893108 | 0.78 | HSD11B1 (0.36) | MAPTHSD11B1NR1H2NR1H3GAA | |
| SCHEMBL9891830 | 0.77 | PIK3CD (0.42) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL9891885 | 0.77 | PIK3CD (0.42) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL9110238 | 0.77 | ATM (0.50) | PIK3CDMAPTHSD11B1NR1H2NR1H3 | |
| SCHEMBL9103248 | 0.77 | ATM (0.50) | PIK3CDMAPTHSD11B1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PIK3CD 999/4885MAPT 4057/4885HSD11B1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.